Brind.

ALS Trial BANYAN Enrolls Patients, Co-funded by ALS Association

1 report, 1 independent Updated Mon 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Tiziana Life Sciences Ltd began administering the first dose of intranasal foralumab to three participants in the BANYAN trial, a Phase 2a study for amyotrophic lateral sclerosis (ALS). The trial, which is testing a fully human anti-CD3 monoclonal antibody, is sponsored by Tiziana and co-funded by the ALS Association. The study is taking place at sites in Boston and Chicago, among others.

From proactiveinvestors.com

Why it matters

Some supportBrind's analysis of the reports

The BANYAN trial is designed to test the safety and tolerability of foralumab in people with early ALS. The co-funding by the ALS Association validates the partnership in advancing research for ALS treatment.

From proactiveinvestors.com

Who's involved

  • ALS AssociationCo-funding the BANYAN clinical trial through its Hoffman ALS Clinical Trial Awards Program
  • BostonLocation of a clinical trial site for the BANYAN study
  • ChicagoLocation of a clinical trial site for the BANYAN study

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • ALS AssociationSpeculative

    The ALS Association might see increased credibility and potential for funding due to its co-funding role in the trial.

  • Project ALSSpeculative

    Project ALS could benefit from the success of the joint research funding partnership, potentially increasing research contracts.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped